• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Duloxetine Atorvastatin Intermediates Companies

    ID: MRFR/HC/6265-CR
    145 Pages
    Rahul Gotadki
    July 2019

    Information about specific intermediate products used in the synthesis of drugs, such as duloxetine and atorvastatin intermediates, can be proprietary and may not be publicly disclosed by the companies involved. However, I can provide general information about the companies that are commonly involved in the production of pharmaceutical intermediates.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Duloxetine Intermediate and Atorvastatin Intermediates Market Research Report - Forecast till 2035 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Duloxetine Atorvastatin Intermediates Market

    Duloxetine Intermediate and Atorvastatin Intermediates Key CompaniesLatest Duloxetine Intermediate and Atorvastatin Intermediates Companies Update



    • June 2023: CMP Pharma, Inc. declared that Atorvaliq (atorvastatin calcium), which had been officially approved by the FDA, is now commercially available. Developed to address elevated cholesterol levels and various cardiovascular disease and stroke risk factors, the medication is a liquid oral suspension that has received approval for use in patients aged 10 years and older. Atorvaliq is specifically designed for a subset of patients who require atorvastatin but experience dysphagia or challenge ingesting tablets. The provision of Atorvaliq as a liquid formulation by the FDA guarantees convenience, safety, and approval for healthcare providers and suitable patients. A 150mL container of Atorvaliq oral suspension contains 20mg/5mL of atorvastatin calcium. There is no refrigeration requirement for this item, and it has a 24-month shelf life.



    • Sun Pharmaceutical Industries, Inc. (Sun Pharma), a wholly owned subsidiary of Sun Pharmaceutical Industries Limited based in Mumbai, declared today that Drizalma Sprinkle™ is now covered by the top ten Medicare Part D plans, which encompass 91% of eligible U.S. lives. Drizalma Sprinkle™ is one of three sprinkle formulation products in Sun Pharma's long-term care (LTC) portfolio. These products are prescribed to the forty percent of American adults who cannot or will not ingest solid medication forms, both inside and outside of LTC facilities. Drizalma Sprinkle™ is the initial and sole sprinkle formulation of delayed-release duloxetine capsules to receive approval from the U.S. Food and Drug Administration (FDA). It is approved for the treatment of generalized anxiety disorder (GAD) in pediatric patients aged 7-17 and major depressive disorder (MDD), diabetic peripheral neuropathy pain (DPNP), and chronic musculoskeletal pain in adults.


    List of Duloxetine Intermediate and Atorvastatin Intermediates Key companies in the market

    • Jiangxi Aifeimu Technology Co., Ltd

    • Zhejiang Jiuzhou Pharmaceutical Co., Ltd,

    • Jigs Chemicals

    • Manus Aktteva

    • Arch Pharmalabs

    • Afine Chemicals Ltd

    • Shodhana Laboratories

    • Fluorochem Ltd

    • Chiral Bio Sciences Ltd

    • Tokyo Chemical Industry Co., Ltd.